These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20083339)

  • 1. Sensory effects of antimuscarinics: still a matter of debate.
    Behr-Roussel D; Giuliano FA
    Eur Urol; 2010 Jul; 58(1):29-30. PubMed ID: 20083339
    [No Abstract]   [Full Text] [Related]  

  • 2. Open to debate. The Motion: antimuscarinics are the mainstay of therapy for overactive bladder.
    Chapple C; Cruz F
    Eur Urol; 2008 Jul; 54(1):226-30. PubMed ID: 18439750
    [No Abstract]   [Full Text] [Related]  

  • 3. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

  • 4. Antimuscarinics and overactive bladder: other mechanism of action.
    Yamaguchi O
    Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical compounds for the treatment of overactive bladder.
    Giannitsas K; Konstantinopoulos A; Patsialas C; Athanasopoulos A; Perimenis P
    Expert Opin Ther Pat; 2009 Feb; 19(2):107-17. PubMed ID: 19441912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local effects of antimuscarinics.
    Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Treating patients with overactive bladder symptoms with antimuscarinics; heart rate considerations.
    Wyllie MG
    BJU Int; 2008 Jan; 101(1):129. PubMed ID: 18086105
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimuscarinics and cognitive function.
    De Ridder D
    Eur Urol; 2006 Aug; 50(2):211-2. PubMed ID: 16632192
    [No Abstract]   [Full Text] [Related]  

  • 10. Fesoterodine (toviaz) for overactive bladder.
    Med Lett Drugs Ther; 2009 May; 51(1311):34-5. PubMed ID: 19417719
    [No Abstract]   [Full Text] [Related]  

  • 11. Antimuscarinics suppress adenosine triphosphate and prostaglandin E2 release from urothelium with potential improvement in detrusor overactivity in rats with cerebral infarction.
    Yokoyama O; Tanaka I; Kusukawa N; Yamauchi H; Ito H; Aoki Y; Oyama N; Miwa Y; Akino H
    J Urol; 2011 Jun; 185(6):2392-7. PubMed ID: 21511278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations.
    Andersson KE; Olshansky B
    BJU Int; 2007 Nov; 100(5):1007-14. PubMed ID: 17922785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug information: Toviaz.
    Physician Assistants' Prescribing Reference
    JAAPA; 2009 Jun; 22(6):12. PubMed ID: 19601442
    [No Abstract]   [Full Text] [Related]  

  • 15. Antimuscarinics for the treatment of neurogenic detrusor overactivity.
    Wyndaele JJ
    Spinal Cord; 2013 Jun; 51(6):431. PubMed ID: 23743497
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. A. J. Wein and R. R. Rackley J Urol, suppl., 2006; 175: S5-S10.
    Löfgren OE
    J Urol; 2007 Oct; 178(4 Pt 1):1553; author reply 1553. PubMed ID: 17707052
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
    Drinka PJ
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):292-3; author reply 293. PubMed ID: 17062331
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in the development of antimuscarinic agents for overactive bladder.
    Smith AL; Wein AJ
    Trends Pharmacol Sci; 2010 Oct; 31(10):470-5. PubMed ID: 20801529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urothelial effects of oral agents for overactive bladder.
    Andersson KE; Fullhase C; Soler R
    Curr Urol Rep; 2008 Nov; 9(6):459-64. PubMed ID: 18947510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing treatments for overactive bladder.
    Waine E; Stott M
    Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.